Tagged with china

Taiwan With the USA and China locked in a trade war, China’s near neighbour Taiwan – with its strong scientific and technology base, political security and economic reliability – may stand to benefit from the situation, attracting more investment from the US and more closely collaborating with US firms and research…

China The US FDA has granted orphan drug designation to Shanghai-headquartered biotech CARsgen Therapeutics’ CAR-T cell therapy CT053 for multiple myeloma after positive results were observed in the phase I trial efficacy evaluation.   19 of 24 patients with relapsed and refractory multiple myeloma showed complete response Zonghai Li, CARSgen Therapeutics…

China Competition is heating up among Asian stock exchanges hoping to lure the hottest prospects in Chinese biotech to list there. The newest competitor, Shanghai’s STAR Board, has already attracted over 100 companies, some of which have reconsidered listing on the Hong Kong Exchange, wary of the HKEX’s lukewarm performance.  …

China Earlier this year, PharmaBoardroom highlighted five of the most innovative and important biotech companies making waves in the world’s second-largest pharmaceutical market, China. Here, we pick out five more firms looking to crack both the Chinese and international markets.   EpimAB Biotherapeutics Founded in 2015, EpimAb Biotherapeutics is a privately owned…

China Dr Kai Lamottke, co-founder and MD of Bicoll GmbH, Munich, and since 2001, GM and board member of Bicoll Biotechnology (Shanghai) Co. Ltd discusses Bicoll’s presence in both the Chinese and European markets, its unique Bicoll Plant ProfilesTM (fine fractions derived from plant extracts fractionated by Bicoll’s innovative isolation system…

China Jim Xu, GM of Medidata China, shares the importance of the China market to Medidata Solutions, the global leader in cloud services and solutions to the life sciences industry; his three priorities to foster stronger customer relationships, build talent, and deliver our offerings locally to the China market; as well…

China Dr. Chris Lu, CEO and cofounder of Laekna Therapeutics, shares Laekna’s ambition to deliver cures and improve the quality of life of patients globally, captured by the word ‘Laekna’, which is Old Norse for ‘to cure, to heal’. He also outlines Laekna’s focus on disease biology, specifically the areas of…

China Tony Acciarito, President of Thermo Fisher Scientific China, explains how he is delivering the company’s mission of ‘enabling our customers to make the world healthier, cleaner and safer’ in China, the importance of entrepreneurial thinking and agility to the China market, the significant investments they have made here, and his…

China Zheru Zhang and Jielun Zhu of I-Mab Biopharma, shares their vision for the ambitious biotech company looking to develop their dual-pronged strategy of in-licensing ‘fast-to-market’ assets for their China portfolio while accelerating proof-of-concept of their internally developed candidates; what it means to operate at ‘I-Mab speed’, not just ‘China Speed’;…

China Junshi Biosciences is an innovation-driven biopharmaceutical company with a focus on discovery and innovative drugs. Dr Li Ning, CEO, discusses being the first Chinese company to successfully launch a domestically-developed PD-1 cancer drug (toripalimab) in China, their commercialization and pricing strategies and the exciting new products and milestones that we…

China Kai Zhang, founder and chairman, and Sonia Wang, CEO, of Chinese respiratory technology specialist Omni Pharmaceuticals, discuss the respiratory market in China, how Omni plans to introduce four respiratory drugs onto the market within two years, and its focus on innovative new technologies.   Unlike oncology, the inhalation market in…

China Transcenta’s Xueming Qian outlines the new company’s origins, the space it seeks to fill within the highly competitive Chinese oncology market, and where Chinese biotech stands globally in 2019.   I did not want to work on an antibody similar to the dozens already in clinical trials, I wanted to…